Evidence map›Paper›PMID 30671435›Full record

ReviewFrontiers in medicine2018

Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies.

Michael Eikmans, Els M Gielis, Kristien J Ledeganck, Jianxin Yang, Daniel Abramowicz, Frans F J Claas

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06825117 (Impact of Probiotic Supplementation on Urinary Tract Infections and Clinically Relevant Outcomes of Kidney Transplant Recipients), which is not on this map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06825117 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Impact of Probiotic Supplementation on Urinary Tract Infections and Clinically Relevant Outcomes of Kidney Transplant Recipients

TypeinterventionalSponsorUniversity Hospital, Udine, ItalyRan2024 to 2028Enrolled132ConditionsUrinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, DysbiosisArmsOMNi-BiOTiC® 41167, Placebo
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael EikmansDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Els M GielisLaboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Kristien J LedeganckLaboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium.
Jianxin YangDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
Daniel AbramowiczDepartment of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium.
Frans F J ClaasDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney transplantation is considered the favored treatment for patients suffering from end-stage renal disease, since successful transplantation is associated with longer survival and improved quality of life compared to dialysis. Alloreactive immune responses against the donor kidney may lead to acute rejection of the transplant. The current diagnosis of renal allograft rejection mainly relies on clinical monitoring, including serum creatinine, proteinuria, and confirmation by histopathologic assessment in the kidney transplant biopsy. These parameters have their limitations. Identification and validation of biomarkers, which correlate with or predict the presence of acute rejection, and which could improve therapeutic decision making, are priorities for the transplantation community. There is a need for alternative, less invasive but sensitive markers to diagnose acute graft rejection. Here, we provide an overview of the current status on research of biomarkers of acute kidney transplant rejection in blood and urine. We specifically discuss relatively novel research strategies in biomarker research, including transcriptomics and proteomics, and elaborate on donor-derived cell-free DNA as a potential biomarker.

Indexed as

acute rejectionbiomarkercell-free DNAkidney transplantationnon-invasiveproteomicstranscriptomicstransplant outcome

Identifiers

PMID30671435
PMCPMC6331461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.